Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.2
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 19683496
Johnson N, et al. (2009) Cdk1 participates in BRCA1-dependent S phase checkpoint control in response to DNA damage. Mol Cell 35, 327-39 19683496
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S1189-p - BRCA1 (human)
Modsite: QKGELsRsPsPFtHT SwissProt Entrez-Gene
Orthologous residues
BRCA1 (human): S1189‑p, BRCA1 iso6 (human): , BRCA1 iso7 (human): S1189‑p, BRCA1 (mouse): S1152‑p, BRCA1 (rat): S1153‑p
Characterization
Methods used to characterize site in vivo mutation of modification site
Disease tissue studied:  lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  NCI-H1299 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE CDK1 (human)
Downstream Regulation
Effect of modification (function):  intracellular localization
Comments:  promotes formation of BRCA1 foci

S1191-p - BRCA1 (human)
Modsite: GELsRsPsPFtHTHL SwissProt Entrez-Gene
Orthologous residues
BRCA1 (human): S1191‑p, BRCA1 iso6 (human): , BRCA1 iso7 (human): S1191‑p, BRCA1 (mouse): S1154‑p, BRCA1 (rat): S1155‑p
Characterization
Methods used to characterize site in vivo mutation of modification site
Disease tissue studied:  lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  NCI-H1299 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE CDK1 (human)
Downstream Regulation
Effect of modification (function):  intracellular localization
Comments:  promotes formation of BRCA1 foci

S1497-p - BRCA1 (human)
Modsite: EPGVERssPsKCPsL SwissProt Entrez-Gene
Orthologous residues
BRCA1 (human): S1497‑p, BRCA1 iso6 (human): S393‑p, BRCA1 iso7 (human): S1518‑p, BRCA1 (mouse): S1454‑p, BRCA1 (rat): S1455‑p
Characterization
Methods used to characterize site in vivo immunoprecipitation, mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  NCI-H1299 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE CDK1 (human)
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
cisplatin increase
doxycycline cisplatin inhibit treatment-induced increase
Downstream Regulation
Effect of modification (function):  intracellular localization
Comments:  promotes formation of BRCA1 foci

Y15-p - CDK1 (human)
Modsite: EkIGEGtyGVVykGR SwissProt Entrez-Gene
Orthologous residues
CDK1 (human): Y15‑p, CDK1 iso2 (human): Y15‑p, CDK1 (mouse): Y15‑p, CDK1 (rat): Y15‑p, CDK1 (chicken): Y15‑p, CDK1 (fruit fly): Y15‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  NCI-H1299 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
cisplatin increase
doxycycline cisplatin inhibit treatment-induced increase

Y15-p - CDK2 (human)
Modsite: EkIGEGtyGVVykAR SwissProt Entrez-Gene
Orthologous residues
CDK2 (human): Y15‑p, CDK2 iso2 (human): Y15‑p, CDK2 (mouse): Y15‑p, CDK2 (rat): Y15‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  NCI-H1299 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
cisplatin increase
doxycycline cisplatin inhibit treatment-induced increase